These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30072015)

  • 1. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
    Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expressions and clinical significances of paired box gene 2 and cyclin D1 in advanced ovarian serous carcinoma].
    Song Y; Zuo J; Huang X; Shen GH; Liu XY; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):891-895. PubMed ID: 29262504
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
    Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
    Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
    Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
    Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas.
    Wang H; Wang H; Makki MS; Wen J; Dai Y; Shi Q; Liu Q; Zhou X; Wang J
    Int J Clin Exp Pathol; 2014; 7(1):264-71. PubMed ID: 24427347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.
    Wu GQ; Xie D; Yang GF; Liao YJ; Mai SJ; Deng HX; Sze J; Guan XY; Zeng YX; Lin MC; Kung HF
    Int J Cancer; 2009 Dec; 125(11):2631-42. PubMed ID: 19672860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
    Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
    Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
    Int J Gynecol Cancer; 2008; 18(4):692-701. PubMed ID: 17944918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.